English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

α4β1 integrins or VLA-4 are found in membranes of monocytes and T lymphocytes. Its participation in leukocyte migration is crucial for inflammatory diseases. Moreover, these proteins are also found in myoblasts and participate in the muscular regeneration process. Therefore, VLA-4 is an important therapeutic target for diseases such as muscular dystrophies, which are associated to the inflammatory process. ScFvs, Single Chain Fragment Variable, are fragments of antibodies which conserve the hipervariable regions of light and heavy chains, preserving their specificity. Currently, the only antibody commercially available, which interacts with α4β1 integrins, is Natalizumab. However, Natalizumab is not specific for α4β1. It also recognizes α4β7 integrins. Beside this, its application is not totally safe. In this context, this work aimed to build a scFv specific for α4β1 integrins through in silico tools and, later, in vitro tools.

Generation of a scFv antagonistic to VLA-4 integrin as potential therapeutic target in muscular dystrophies: in silico phase